COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

30,797 Articles (22,527 medRxiv, 8,270 bioRxiv)

Most recent first Previous |  Page 144: Articles 1431-1440  | Next

Omicron-specific ultra-potent SARS-CoV-2 neutralizing antibodies targeting the N1/N2 loop of Spike N-terminal domain
Niu, X., Li, Z., Wang, J., Jian, F., Yu, Y., Song, W., Yisimayi, A., Du, S., Zhang, Z., Wang, Q., Wang, J., An, R., Wang, Y., Wang, P., Sun, H., Yu, L., Yang, S., Xiao, T., Gu, Q., Shao, F., Wang, Y., Xiao, J., Cao, Y.
10.1101/2024.07.10.602843 — Posted: 2024-07-10
Global siRNA Screen Reveals Critical Human Host Factors of SARS-CoV-2 Multicycle Replication
Yin, X., Pu, Y., Yuan, S., Pache, L., Churas, C., Weston, S., Riva, L., Simons, L. M., Cisneros, W., Clausen, T., de Jesus, P., Kim, H. N., Fuentes, D., Whitelock, J., Esko, J., Lord, M., Mena, I., Garcia-Sastre, A., Hultquist, J., Frieman, M., Ideker, T., Pratt, D., Martin-Sancho, L., Chanda, S.
10.1101/2024.07.10.602835 — Posted: 2024-07-10
Impact of the COVID-19 pandemic and vaccination on global, regional, and national burden of Guillain-Barre syndrome: observational study
Gao, X., Zhao, C., Yang, J., Yang, Z., Feng, J., Zhan, S., Fan, D., Liu, Z.
10.1101/2024.07.09.24309613 — Posted: 2024-07-10
Differential circulating proteomic responses associated with ancestry during severe COVID-19 infection
Zheng, T. M., Ilboudo, Y., Lu, T., Butler-Laporte, G., Nakanishi, T., Morrison, D., Adra, D., Richards, J. B.
10.1101/2024.07.09.24310087 — Posted: 2024-07-10
SARS-CoV-2 shedding dynamics in human respiratory tract
Jin, X., Ren, L., Ren, X., Wang, J.
10.1101/2024.07.09.602697 — Posted: 2024-07-09
Associations between social network characteristics and COVID-19 vaccination intention: the SaNAE study
Steijvers, L. C., van Bilsen, C. J., Brinkhues, S., Stutterheim, S. E., Crutzen, R., Ruiter, R. A., Hoebe, C. J., Dukers-Muijrers, N. H.
10.1101/2024.07.08.24309958 — Posted: 2024-07-08
SARS-CoV-2 neutralization and protection of hamsters via nasal administration of a humanized neutralizing antibody
Lebedin, M., Petrovsky, N., Tabynov, K., Tabynov, K., Lebedin, Y.
10.1101/2024.07.08.602557 — Posted: 2024-07-08
NSP4 mutation T492I drives rapid evolution of SARS-CoV-2 toward Omicron
Lin, X., Sha, Z., Zhang, C., Adler, J. M., Vidal, R. M., Langner, C., Fu, B., Xiong, Y., Tan, M., Jiang, C., Zeng, H., Zhang, X., Li, Q., Yan, J., Lu, X., Wang, S., Mao, X., Kunec, D., Trimpert, J., Wu, H., Zou, Q., Zhu, Z.
10.1101/2024.07.05.602217 — Posted: 2024-07-08
Early 2022 breakthrough infection sera from India target the conserved cryptic class 5 epitope to counteract immune escape by SARS-CoV-2 variants
Das Jana, I., Kanjo, K., Roy, S., Bhasin, M., Bhattacharya, S., Banerjee, I., Jana, S., Chatterjee, A., Chakraborty, A., Chakraborty, S., Mukherjee, B., Varadarajan, R., Mondal, A.
10.1101/2024.07.08.602485 — Posted: 2024-07-08
Structural impact of synonymous mutations in six SARS-CoV-2 Variants of Concern
Ziesel, A., Jabbari, H.
10.1101/2024.07.06.602340 — Posted: 2024-07-08

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).